title: Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry.
abstract: The aim of this study was to evaluate the prevention of recurrent deep vein thrombosis (R-DVT) with an oral antithrombotic agent (sulodexide) in moderate to high-risk subjects. A group of 405 patients was included into the multicenter registry. Both compression and an exercise program were used as well as a risk-factors control plan. After diagnosis of DVT, patients were treated with oral anticoagulants for 6 months. At the end of this period a coagulation study was made and patients started treatment with oral sulodexide capsules for a period of 24 months. The femoral, popliteal, tibial, and superficial veins were scanned with high-resolution ultrasound at inclusion;scans were repeated at 6, 12, 18, and 24 months. Of the 405 subjects included into the registry 178 in the control group (mean age 52.2; SD 11; M:F=90:88) and 189 in the treatment group (mean age 53.2; SD 10.3; M:F=93:96) completed the analysis period of 24 months. At 6 and 12 months the incidence of R-DVT was lower (p<0.05) in the treatment group. At 24 months the global incidence of R-DVT was 17.9% in the control group and 7.4% in the sulodexide group (p<0.05), 2.42 times lower than in controls. The 2 groups were comparable for age and sex distribution and for the localization of the thrombi at inclusion. Also the 2 groups of dropouts were comparable. In the control group there were 32 recurrent DVTs and 24 subjects lost to follow-up (total of 56) of 202 included subjects (27.7%) in comparison with 28 failures (14 recurrent DVTs and 14 lost subjects) of 203 subjects (13.8%) in the treatment group. This difference was statistically significant. In this analysis the incidence of DVT in controls was 2.07 times higher than in the treatment group subjects. In conclusion sulodexide was effective in reducing recurrent thrombotic events in high-risk subjects.
authors.affiliation: General Surgery Osp. Guardiagrele (Ch), University of Milan, Italy.
authors.forename: B M
authors.initials: BM
authors.lastname: Errichi
authors.forename: M R
authors.initials: MR
authors.lastname: Cesarone
authors.forename: G
authors.initials: G
authors.lastname: Belcaro
authors.forename: R
authors.initials: R
authors.lastname: Marinucci
authors.forename: A
authors.initials: A
authors.lastname: Ricci
authors.forename: A
authors.initials: A
authors.lastname: Ippolito
authors.forename: R
authors.initials: R
authors.lastname: Brandolini
authors.forename: G
authors.initials: G
authors.lastname: Vinciguerra
authors.forename: M
authors.initials: M
authors.lastname: Dugall
authors.forename: A
authors.initials: A
authors.lastname: Felicita
authors.forename: L
authors.initials: L
authors.lastname: Pellegrini
authors.forename: G
authors.initials: G
authors.lastname: Gizzi
authors.forename: M
authors.initials: M
authors.lastname: Ruffini
authors.forename: G
authors.initials: G
authors.lastname: Acerbi
authors.forename: P
authors.initials: P
authors.lastname: Bavera
authors.forename: A Di
authors.initials: AD
authors.lastname: Renzo
authors.forename: M
authors.initials: M
authors.lastname: Corsi
authors.forename: M
authors.initials: M
authors.lastname: Scoccianti
authors.forename: M
authors.initials: M
authors.lastname: Hosoi
authors.forename: M
authors.initials: M
authors.lastname: Lania
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D005260:Female; D005500:Follow-Up Studies; D006025:Glycosaminoglycans / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D006801:Humans; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D012042:Registries; D012307:Risk Factors; D055502:Secondary Prevention; D014463:Ultrasonography; D020246:Venous Thrombosis / Q000000981:diagnostic imaging / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D006025:Glycosaminoglycans; C007858:glucuronyl glucosamine glycan sulfate